首页> 中文期刊> 《世界临床病例杂志》 >Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy

Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy

         

摘要

BACKGROUND Chronic hepatitis B virus infection remains a major global public health problem.Peginterferon-alpha-2a(PEG-IFN)has direct antiviral and immunoregulatory effects,and it has become one of the first choice drugs for the treatment of chronic hepatitis B(CHB).Cytokines play an important role in immunity,and they directly inhibit viral replication and indirectly determine the predominant pattern of the host immune response.AIM To determine the correlation between cytokine/chemokine expression levels and response to PEG-IFN treatment in patients with CHB.METHODS Forty-six kinds of cytokines were analyzed before PEG-IFN therapy and at 24 wk during therapy in 26 CHB patients.RESULTS The monokine induced by INF-γ(CXCL9)and serum interferon-inducible protein 10(IP-10)levels at baseline were higher in virological responders than in nonvirological responders(NRs)and decreased during treatment,whereas the NRs did not exhibit significant changes.The macrophage inflammatory protein 1d(MIP-1d)levels at baseline and during treatment were significantly higher in the virological responders than in the NRs,while thymus and activation-regulated chemokine(TARC)levels at baseline and during treatment were significantly lower in the virological responders than in the NRs.The CXCL9,IP-10,MIP-1d,and TARC baseline levels exhibited the expected effects for interferon treatment.The area under the receiver operating characteristic curve values of CXCL9,IP-10,MIP-1d,and TARC for predicting virological responses were 0.787,0.799,0.787,and 0.77(P=0.01,0.013,0.01,and 0.021),respectively.CONCLUSION We found that cytokine levels before and during treatment may represent potential biomarkers to select CHB patients who can respond to PEG-IFN.Therefore,cytokines can be used as an indicator of antiviral drug selection before CHB treatment.

著录项

  • 来源
    《世界临床病例杂志》 |2020年第11期|P.2255-2265|共11页
  • 作者单位

    The First Clinical Medical School Lanzhou University Lanzhou 730000 Gansu Province China;

    The First Clinical Medical School Lanzhou University Lanzhou 730000 Gansu Province ChinaLaboratory Department of the First Hospital of Lanzhou University Lanzhou 730000 Gansu Province China;

    The First Clinical Medical School Lanzhou University Lanzhou 730000 Gansu Province China;

    The First Clinical Medical School Lanzhou University Lanzhou 730000 Gansu Province China;

    The First Clinical Medical School Lanzhou University Lanzhou 730000 Gansu Province China;

    Special Minimally Invasive Surgery Department The First Hospital of Lanzhou University Lanzhou 730000 Gansu Province China;

    Special Minimally Invasive Surgery Department The First Hospital of Lanzhou University Lanzhou 730000 Gansu Province China;

    Special Minimally Invasive Surgery Department The First Hospital of Lanzhou University Lanzhou 730000 Gansu Province China;

    Special Minimally Invasive Surgery Department The First Hospital of Lanzhou University Lanzhou 730000 Gansu Province China;

    The First Clinical Medical School Lanzhou University Lanzhou 730000 Gansu Province ChinaSpecial Minimally Invasive Surgery Department The First Hospital of Lanzhou University Lanzhou 730000 Gansu Province ChinaInstitute of Genetics School of Basic Medical Sciences Lanzhou University Lanzhou 730000 Gansu Province ChinaInstitute of Hepatopancreatobiliary of Gansu Province Lanzhou 730000 Gansu Province ChinaoKey Laboratory of Biotherapy and Regenerative Medicine of Gansu Province Lanzhou 730000 Gansu Province China;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类 传染病;
  • 关键词

    Chronic hepatitis B; Peginterferon-alpha-2a; Cytokine/chemokine; CXCL9; Interferon-inducible protein 10; Thymus and activation-regulated chemokine;

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号